SG11201807401RA - Therapeutic membrane vesicles - Google Patents
Therapeutic membrane vesiclesInfo
- Publication number
- SG11201807401RA SG11201807401RA SG11201807401RA SG11201807401RA SG11201807401RA SG 11201807401R A SG11201807401R A SG 11201807401RA SG 11201807401R A SG11201807401R A SG 11201807401RA SG 11201807401R A SG11201807401R A SG 11201807401RA SG 11201807401R A SG11201807401R A SG 11201807401RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vesicles
- membrane vesicles
- codiak
- biosciences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011101111011 MIMI 010110111110111011# International Bureau ... .... ..Yjd ..... ...,/ (10) International Publication Number (43) International Publication Date WO 2017/161010 Al 21 September 2017 (21.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CO7K 1/30 (2006.01) GO1N 1/34 (2006.01) kind of national protection available): AE, AG, AL, AM, C12N 15/90 (2006.01) GO1N 1/38 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C12Q 1/68 (2006.01) G01N 33/50 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/022544 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (22) International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 15 March 2017 (15.03.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (25) Filing Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (26) Publication Language: English ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/308,805 15 March 2016 (15.03.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: CODIAK BIOSCIENCES, INC. [US/US]; TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 500 Technology Square, 9th Floor, Cambridge, Massachu- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, setts 02139 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: LOTVALL, Jan; Codiak BioSciences, Inc., LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 500 Technology Square, 9th Floor, Cambridge, Massachu- _ setts 02139 (US). JANG, Su, Chul; Codiak BioSciences, GW, KM, ML, MR, NE, SN, TD, TG). — Inc., 500 Technology Square, 9th Floor, Cambridge, Mas- Declarations under Rule 4.17: — sachusetts 02139 (US). — — of inventorship (Rule 4.17(iv)) Agents: SUN, Danqiong Fenwick LLP, 801 = (74) et al.; & West Published: California Street, Mountain View, CA 94041 (US). — with international search report (Art. 21(3)) = = = = (54) Title: THERAPEUTIC MEMBRANE VESICLES = Figure 1 = = Antibody or aptamer bead conjugation bead = = = = _ = EV 1-1 3 / 3 © 61. Elution Il © Il Sub-populations of EV Il IN 1-1 (57) : The present invention relates to a method for producing membrane vesicles from extracellular vesicles or organelles 0 and therapeutic membrane vesicles produced by such method. The invention further relates to therapeutic membrane vesicles, a \" method of treating a metabolic disorder by using such vesicles and such vesicles for use in therapy, such as in treatment of a meta - C bolic disorder. The invention further relates to a method of producing a membrane vesicle from an organelle. In addition, the present invention relates to a method of separating a sub-population of extracellular vesicles from an extracellular vesicle bulk.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662308805P | 2016-03-15 | 2016-03-15 | |
PCT/US2017/022544 WO2017161010A1 (en) | 2016-03-15 | 2017-03-15 | Therapeutic membrane vesicles |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807401RA true SG11201807401RA (en) | 2018-09-27 |
Family
ID=59852310
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807401RA SG11201807401RA (en) | 2016-03-15 | 2017-03-15 | Therapeutic membrane vesicles |
SG10202008883SA SG10202008883SA (en) | 2016-03-15 | 2017-03-15 | Therapeutic membrane vesicles |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202008883SA SG10202008883SA (en) | 2016-03-15 | 2017-03-15 | Therapeutic membrane vesicles |
Country Status (13)
Country | Link |
---|---|
US (1) | US20200155703A1 (en) |
EP (1) | EP3430024A4 (en) |
JP (1) | JP2019513019A (en) |
KR (1) | KR20180122433A (en) |
CN (1) | CN109071597A (en) |
AU (1) | AU2017232498A1 (en) |
BR (1) | BR112018068746A2 (en) |
CA (1) | CA3017586A1 (en) |
IL (1) | IL261490A (en) |
MX (1) | MX2018011202A (en) |
RU (1) | RU2018136151A (en) |
SG (2) | SG11201807401RA (en) |
WO (1) | WO2017161010A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018520125A (en) | 2015-06-10 | 2018-07-26 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | Use of exosomes for treatment of disease |
EP3548003A4 (en) | 2016-11-30 | 2020-07-22 | The Regents of The University of California | Extracellular vesicles and methods and uses thereof |
CN110869507A (en) | 2017-05-08 | 2020-03-06 | 旗舰先锋创新V股份有限公司 | Composition for promoting membrane fusion and use thereof |
CA3072352A1 (en) | 2017-08-25 | 2019-02-28 | Codiak Biosciences, Inc. | Preparation of therapeutic exosomes using membrane proteins |
GB2574785A (en) | 2017-09-15 | 2019-12-25 | Jan Loetvall | Method and system for identifying membrane proteins on extracellular vesicles |
WO2019108957A1 (en) * | 2017-12-01 | 2019-06-06 | Alxerion Biotech Corp. | Device and system for loaded cellular vesicles and uses thereof |
AU2018386209A1 (en) * | 2017-12-14 | 2020-07-30 | Mayo Foundation For Medical Education And Research | Purified exosome products, method of making, and methods of using |
SG11202005049QA (en) | 2017-12-28 | 2020-07-29 | Codiak Biosciences Inc | Exosomes for immuno-oncology and anti-inflammatory therapy |
EA202091486A1 (en) * | 2018-02-12 | 2021-02-08 | Кодиак Байосайенсес, Инк. | METHODS AND COMPOSITIONS FOR MACROPHAGES POLARIZATION |
US20210137839A1 (en) | 2018-02-17 | 2021-05-13 | Flagship Pioneering Innovations V, Inc. | Compositions and methods for membrane protein delivery |
WO2019186558A1 (en) | 2018-03-29 | 2019-10-03 | Technion Research And Development Foundation Limited | Vesicles comprising a pten inhibitor and uses of same |
EP3773492A4 (en) * | 2018-04-09 | 2022-01-05 | Board of Regents, The University of Texas System | Therapeutic targeting of oncogenes using exosomes |
AU2019378036A1 (en) | 2018-11-14 | 2021-06-03 | Flagship Pioneering Innovations V, Inc | Compositions and methods for compartment-specific cargo delivery |
FR3091296B1 (en) * | 2018-12-28 | 2021-02-19 | Univ De Lorraine | FLUIDIC SYSTEM FOR THE PRODUCTION OF EXTRACELLULAR VESICLES INCLUDING A THERAPEUTIC OR IMAGING AGENT AND ASSOCIATED PROCESS |
US20220080035A1 (en) * | 2019-01-09 | 2022-03-17 | Exocure Biosciences, Inc. | Bacteria-derived vesicles and uses thereof |
CN109913407B (en) * | 2019-02-22 | 2021-03-23 | 浙江大学 | Preparation method and application of adipose-derived mesenchymal stem cell exosomes |
WO2020207426A1 (en) * | 2019-04-10 | 2020-10-15 | 上海交通大学医学院附属上海儿童医学中心 | In vivo implantable micropore pocket, use method therefor and application thereof |
CA3147369A1 (en) * | 2019-08-14 | 2021-02-18 | Dalia BURZYN | Extracellular vesicle-aso constructs targeting cebp/beta |
CN114641570A (en) * | 2019-08-14 | 2022-06-17 | 科迪亚克生物科学公司 | Extracellular vesicles with KRAS-targeted antisense oligonucleotides |
CA3147680A1 (en) * | 2019-08-14 | 2021-02-18 | Dalia BURZYN | Extracellular vesicle-aso constructs targeting stat6 |
WO2021030773A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
CA3147366A1 (en) * | 2019-08-14 | 2021-02-18 | Adam T. BOUTIN | Extracellular vesicles with stat3-antisense oligonucleotides |
EP4022074A4 (en) * | 2019-08-27 | 2023-11-15 | The Trustees of Columbia University in the City of New York | Engineered exosomes for targeted delivery |
US20220333132A1 (en) | 2019-09-03 | 2022-10-20 | Sana Blotechnology, Inc. | Cd24-associated particles and related methods and uses thereof |
IT201900024580A1 (en) | 2019-12-18 | 2021-06-18 | Consiglio Nazionale Ricerche | EXTRACELLULAR VESICLES FROM MICROALGAE |
AU2021215935A1 (en) | 2020-02-05 | 2022-08-25 | Diadem Biotherapeutics Inc. | Artificial synapses |
EP4119166A1 (en) | 2020-03-12 | 2023-01-18 | Institute for Basic Science | Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition |
CN111500607B (en) * | 2020-03-13 | 2022-05-03 | 首都医科大学附属北京口腔医院 | Fusion gene for peri-implant anti-inflammation, exosome, biological coating, preparation method and application |
WO2021202604A1 (en) | 2020-03-31 | 2021-10-07 | Sana Biotechnology, Inc. | Targeted lipid particles and compositions and uses thereof |
IL305171A (en) * | 2021-02-17 | 2023-10-01 | Lonza Sales Ag | Extracellular vesicle-nlrp3 antagonist |
IL308836A (en) | 2021-05-28 | 2024-01-01 | Sana Biotechnology Inc | Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses |
CA3226019A1 (en) | 2021-07-20 | 2023-01-26 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their preparation, and uses |
IT202100027725A1 (en) * | 2021-10-28 | 2023-04-28 | Torino Politecnico | METHOD FOR OBTAINING CONCENTRATED POPULATIONS OF EXTRACELLULAR VESICULES WASHED OF THEIR PHYSIO-PATHOLOGICAL LOAD |
WO2023142999A1 (en) * | 2022-01-27 | 2023-08-03 | 国家纳米科学中心 | Nucleic acid nano vaccine derived from bacterial outermembrane vesicle and use thereof |
WO2023144127A1 (en) | 2022-01-31 | 2023-08-03 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon administration, and uses |
WO2023178500A1 (en) * | 2022-03-22 | 2023-09-28 | Beijing Theraxyte Bioscience Co. Ltd. | Therapeutic vesicles and methods of processing the same |
WO2023232976A1 (en) | 2022-06-03 | 2023-12-07 | Ags Therapeutics Sas | Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses |
CN114908046B (en) * | 2022-06-16 | 2024-01-02 | 四川大学 | Preparation method of mitochondrial membrane vesicles |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024059174A1 (en) * | 2022-09-14 | 2024-03-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
JP7371975B1 (en) | 2022-09-27 | 2023-10-31 | セルソース株式会社 | Method for producing extracellular vesicles and composition containing extracellular vesicles |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024088808A1 (en) | 2022-10-24 | 2024-05-02 | Ags Therapeutics Sas | Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0416120D0 (en) * | 2004-07-19 | 2004-08-18 | Health Prot Agency | Stable compositions containing OMV's |
US9085778B2 (en) * | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
WO2009130649A2 (en) * | 2008-04-21 | 2009-10-29 | Nanoxis Ab | Plasma membrane vesicles and methods of making and using same |
US20130273544A1 (en) * | 2012-04-17 | 2013-10-17 | Life Technologies Corporation | Methods and compositions for exosome isolation |
SI3076949T1 (en) * | 2013-12-04 | 2020-01-31 | Board Of Regents, The University Of Texas System | Method for isolating cancer cell-derived exoxomes |
MX2016007327A (en) * | 2013-12-12 | 2017-03-06 | Broad Inst Inc | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components. |
-
2017
- 2017-03-15 WO PCT/US2017/022544 patent/WO2017161010A1/en active Application Filing
- 2017-03-15 BR BR112018068746A patent/BR112018068746A2/en not_active IP Right Cessation
- 2017-03-15 KR KR1020187029763A patent/KR20180122433A/en not_active Application Discontinuation
- 2017-03-15 JP JP2018548834A patent/JP2019513019A/en active Pending
- 2017-03-15 EP EP17767451.2A patent/EP3430024A4/en not_active Withdrawn
- 2017-03-15 AU AU2017232498A patent/AU2017232498A1/en not_active Abandoned
- 2017-03-15 SG SG11201807401RA patent/SG11201807401RA/en unknown
- 2017-03-15 CA CA3017586A patent/CA3017586A1/en not_active Abandoned
- 2017-03-15 CN CN201780017785.5A patent/CN109071597A/en active Pending
- 2017-03-15 SG SG10202008883SA patent/SG10202008883SA/en unknown
- 2017-03-15 MX MX2018011202A patent/MX2018011202A/en unknown
- 2017-03-15 RU RU2018136151A patent/RU2018136151A/en not_active Application Discontinuation
- 2017-03-15 US US16/084,169 patent/US20200155703A1/en not_active Abandoned
-
2018
- 2018-08-30 IL IL261490A patent/IL261490A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN109071597A (en) | 2018-12-21 |
CA3017586A1 (en) | 2017-09-21 |
KR20180122433A (en) | 2018-11-12 |
US20200155703A1 (en) | 2020-05-21 |
JP2019513019A (en) | 2019-05-23 |
SG10202008883SA (en) | 2020-10-29 |
EP3430024A1 (en) | 2019-01-23 |
RU2018136151A (en) | 2020-04-15 |
EP3430024A4 (en) | 2019-11-13 |
BR112018068746A2 (en) | 2019-01-22 |
AU2017232498A1 (en) | 2018-10-18 |
RU2018136151A3 (en) | 2020-08-03 |
IL261490A (en) | 2018-10-31 |
WO2017161010A1 (en) | 2017-09-21 |
MX2018011202A (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201807188VA (en) | Modified cells for immunotherapy | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201407579QA (en) | Interleukin-2 fusion proteins and uses thereof | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same |